USPTO serial 87975639
NAVICAN
Reviewed by CopyMark Law Group
Reg. 5292993Status 710
- Filing date
- Status date
- Registration date
- Sep 19, 2017
- Examiner
- SHINER, MARK W
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with NAVICAN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Pharmaceutical procurement services, namely, purchasing pharmaceuticals for others; pharmaceutical cost management services and drug utilization review services; assisting patients in enrolling in diagnostics and pharmaceutical reimbursement programs of others; providing business, pricing, reimbursement benchmarking and other market intelligence information in the field of drug reimbursement for prescribers, patients and the pharmaceutical industry; providing business, pricing, reimbursement benchmarking and other market intelligence information in the field of diagnostics reimbursement for providers and patients; business administration of diagnostics and pharmacy reimbursement programs and services; business management and consultation services in the field of specialty pharmacy, namely, assisting patients and providers with pharmaceutical reimbursement; business management and consultation services in the field of off label pharmaceuticals, namely, assisting patients and providers with pharmaceutical reimbursement; business management services in the field of diagnostics, namely, assisting patients and providers with diagnostics reimbursement; and promoting collaboration within the scientific, research and medical communities to achieve advances in the fields of healthcare and pharmaceuticals; business management of comprehensive programs involving drug therapy | SECTION 8 - CANCELLED | May 12, 2017 |
| 036 | Pharmaceutical benefit management services; insurance claims processing in the field of diagnostics and pharmaceutical claims; providing a database featuring information and statistics about patient reimbursement and insurance coverage for diagnostics and pharmaceuticals; and reimbursement payment processing in the field of diagnostics and pharmaceutical claims; and providing information in the field of financial support options and resources for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of drug reimbursement for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of diagnostics reimbursement for providers and patients; financial administration of diagnostics and pharmacy reimbursement programs and services | SECTION 8 - CANCELLED | May 12, 2017 |
| 042 | Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products | SECTION 8 - CANCELLED | May 12, 2017 |
| 044 | Dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive treatment programs involving drug therapy; physician support services in the nature of providing consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship, and other related medical information in the field of oncology; providing a database in the field of oncology and featuring inputting and collection of data and information all for treatment and diagnosis purposes; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; providing an online searchable database in the fields of oncolology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancer | SECTION 8 - CANCELLED | May 12, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Intermountain Insights, LLC
- Other trademarks owned by Intermountain Insights, LLC
- Other trademarks owned by Intermountain Insights, LLC
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NAVICAN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 29, 2024 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 19, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 19, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 18, 2017 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 17, 2017 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Aug 1, 2017 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 1, 2017 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jul 21, 2017 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 30, 2017 | IUAF | USE AMENDMENT FILED | — |
| Jun 30, 2017 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jun 30, 2017 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jun 30, 2017 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 3, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 8, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 8, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 19, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 4, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 27, 2016 | ALIE | ASSIGNED TO LIE | — |
| Sep 14, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 14, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 14, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 14, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 14, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 7, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 14, 2016 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Jul 14, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 6, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 4, 2016 | NWAP | NEW APPLICATION ENTERED | — |